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Burkitt lymphoma (BL) can often be cured by intensive chemotherapy, but the 
toxicity of such therapy precludes its use in the elderly and in patients with endemic BL 
in developing countries, necessitating new strategies1. The normal germinal center B cell 
is the presumed cell of origin for both BL and diffuse large B cell lymphoma (DLBCL), 
yet gene expression analysis suggests that these malignancies may utilize different 
oncogenic pathways2. BL is subdivided into a sporadic subtype (sBL) that is diagnosed in 
developed countries, the EBV-associated endemic subtype (eBL), and an HIV-associated 
subtype (hivBL), but it is unclear whether these subtypes employ similar or divergent 
oncogenic mechanisms. Here we used high throughput RNA sequencing and RNA 
interference screening to discover essential regulatory pathways in BL that cooperate 
with MYC, the defining oncogene of this cancer. In 70% of sBL cases, mutations 
affecting the transcription factor TCF3 (E2A) or its negative regulator ID3 fostered TCF3 
dependency. TCF3 activated the pro-survival PI(3) kinase pathway in BL, in part by 
augmenting tonic B cell receptor signaling. In 38% of sBL cases, oncogenic CCND3 
mutations produced highly stable cyclin D3 isoforms that drive cell cycle progression. 
These findings suggest opportunities to improve therapy for patients with BL. 
We performed RNA resequencing (RNA-seq) on 28 sBL patient biopsies and 13 
BL cell lines and reanalyzed published RNA-seq data from 52 germinal center B cell-like 
(GCB) DLBCL cases and 28 activated B cell-like (ABC) DLBCL cases3. Elimination of 
known single nucleotide polymorphisms left a set of putative SNVs (pSNVs) of which 
95% (495/518) were confirmed by Sanger sequencing (Supplementary Tables 1 and 2).  
Mutations in many genes were more frequent in BL than in DLBCL, including 
MYC as well as many not previously implicated in this lymphoma subtype (Fig. 1; 
Supplementary Fig. 1a; Supplementary Table 1). Conversely, recurrently mutated genes 
in DLBCL3-7 (EZH2, SGK1, BCL2, CD79B, MYD88) were rarely if ever mutated in BL. 
Several genes were mutated in BL and DLBCL (TP53, GNA13, MKI67, CCND3), 
although TP53 mutations were more common in BL (Fig. 1; Supplementary Fig. 1b). 
This mutational survey suggests that BL is pathogenetically distinct from other germinal 
center-derived lymphomas.  
Highly recurrent mutations in TCF3 and its negative regulator ID3 suggested that 
TCF3 plays a central role in BL pathogenesis, as it does in normal B cell development by 
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regulating the transcription of immunoglobulin and other B cell-restricted genes through 
E-box motifs8,9. ID3 and/or TCF3 mutations were present in sBL, hivBL, and eBL, in 
70%, 67%, and 40% of samples, respectively, but these mutations were rare in other 
lymphoid cancers (Fig. 2a; Supplementary Table 3). In sBL, ID3 mutations (58%) were 
more common than TCF3 mutations (11%), and some tumors had mutations in both 
genes (13%). ID3 mutations were usually bi-allelic whereas TCF3 mutations were often 
mono-allelic (Supplementary Fig. 2a; Supplementary Table 3). A somatic origin was 
confirmed for 14 ID3 mutations and 4 TCF3 mutations (Supplementary Table 3). All 
TCF3 mutations affected the basic helix-loop-helix (B-HLH) DNA binding and 
dimerization domain of one TCF3 splice isoform (E47) but not the other (E12), 
suggesting a non-redundant role for E47 in BL pathogenesis. In cases with TCF3 
mutations, E47 was more highly expressed than E12, suggesting gain-of-function 
(Supplementary Fig. 2b). 
Most TCF3 mutations target 4 evolutionarily conserved residues in the B-HLH 
region (N551K, V557E/G, D561E/V/N, M572K; Supplementary Fig. 3a). The most 
common mutations affect V557 and D561, which are adjacent in the crystal structure and 
face away from DNA, suggesting a role in intermolecular interactions (Fig. 2b). The B-
HLH domain may be distorted by mutations affecting M572 and L597, which are 
neighboring residues in crystal structure. N551 is a DNA contact residue10, suggesting 
that N551K could alter TCF3 DNA binding. 
A variety of nonsense and frameshift mutations inactivate ID3 in BL tumors, 
suggesting a tumor suppressor mechanism (Supplementary Fig. 3b). Many missense 
mutations target the conserved loop region of ID3, potentially changing the tertiary 
structure of the B-HLH domain and impairing its ability to inhibit TCF311 (Fig. 2c). 
Numerous ID3 missense mutations affect the HLH domain away from the interface of the 
two helices, possibly altering TCF3 interaction. Other mutations disrupt an ID3 splice 
donor and force a cryptic splice donor to be used, thereby deleting residues V82-Q100 
(Supplementary Figs. 2c, 3b). 
An RNA interference screen revealed TCF3 to be an essential gene in BL lines 
(Supplementary Fig. 2d, Supplementary Table 4), supporting the notion that the TCF3 
and ID3 mutations in BL promote TCF3 action. TCF3 knockdown caused a time-
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dependent toxicity in all BL lines, irrespective of ID3/TCF3 mutations, but had no effect 
on DLBCL lines (Fig. 2d; Supplementary Figs. 2e, 4a, 4b). Wild-type TCF3 rescued BL 
lines from shTCF3 toxicity as could the TCF3 mutants, suggesting that they are not loss-
of-function (Supplementary Fig. 2e). Introduction of wild-type ID3 into BL lines with 
ID3 mutations was lethal, but BL-derived ID3 mutants had less or no toxicity, consistent 
with a tumor suppressor mechanism (Fig. 2e; Supplementary Figs. 2g, 4c). 
The common ID3 and TCF3 mutants diminished their inhibitory 
heterodimerization.  V557E and D561E TCF3 did not associate well with ID3 and failed 
to stabilize ID3 protein expression, unlike wild-type TCF3 (Fig. 2f; Supplementary Fig. 
2h, 4d).  Likewise, the ID3 mutant proteins were expressed less well than wild type ID3 
and were less able to co-immunoprecipitate TCF3 (Fig. 2g; Supplementary Fig. 4e). 
However, N551K TCF3 behaved like wild-type TCF3 in these dimerization assays, 
suggesting a distinct mechanism. 
We next used ChIP-seq analysis to gauge the ability of the  
TCF3 mutants to interact with chromatin genome-wide. We engineered 2 BL lines 
to express biotinylated wild-type or mutant TCF3 isoforms (“TCF3-Biotag”; see 
Methods), allowing us to precipitate bound chromatin with streptavidin. For comparison, 
we used anti-TCF3 antibodies to precipitate chromatin in unmanipulated BL cells 
(Supplementary Table 5). Both the endogenous and TCF3-Biotag ChIP-seq peaks were 
enriched for E-box motifs (CAG(G/C)TG) and overlapped extensively (Supplementary 
Fig. 5a). In 25-bp bins bound by wild-type TCF3-Biotag, the V557E, D561E, and N551K 
isoforms had overlapping ChIP-seq tags (>7) in 98%, 98% and 92% of instances, 
respectively, but the overlap was only 10% for control Biotag ChIP-seq data (p<10-300). 
Hence, all TCF3 mutants bound a large number of genomic targets equivalently. 
Given the lower overlap between N551K and wild-type TCF3 chromatin binding, 
we identified genomic regions that had 4-fold greater (n=212) or lesser (n=139) 
association with wild-type TCF3 than N551K TCF3 (p<10-10) (Supplementary Table 6, 
Supplementary Fig. 5b). In these binding regions, V557E and D561E TCF3 behaved like 
wild-type TCF3. The peaks bound preferentially by wild-type TCF3 contained multiple 
copies of the motif 5’-NNCACCTG-3’ whereas the peaks bound preferentially by N551K 
were enriched for the sequence 5’-GGCAGCTG-3’ (Fig. 2h). While both motifs match 
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the E-box consensus, these results suggest that N551K TCF3 is an altered specificity 
mutant that has somewhat different genomic targets than wild-type TCF3. 
To gain insight into the biological processes controlled by TCF3 in BL, we 
profiled changes in gene expression following TCF3 knockdown or wild-type ID3 
expression in ID3-mutant BL lines. We identified 139 “TCF3-upregulated” genes that 
were decreased in expression by both manipulations and 166 “TCF3-downregulated” 
genes that were increased in expression (FDR=0.017; Fig. 2i; Supplementary Figs. 6a, 
2i). TCF3 ChIP-seq peaks were enriched among TCF3-upregulated genes (58%; 
p=1.81x10-29) and among TCF3–downregulated genes (32%; p=1.03x10-4) 
(Supplementary Fig. 6a). We will refer to such genes as “TCF3 direct targets”. 
Most TCF3-upregulated genes were more highly expressed in BL than in DLBCL 
whereas TCF3-downregulated genes were generally expressed at lower levels in BL 
(p≤0.001; Fig. 2i; Supplementary Figs. 6a, b). BL tumors with ID3 and/or TCF3 
mutations had higher expression of the TCF3-upregulated signature than tumors with 
wild-type ID3 and TCF3, and the opposite was true for the TCF3-downregulated 
signature (p=0.0001; Supplementary Fig. 6c). Hence, the transcriptional influence of 
TCF3 on the BL phenotype appears to be accentuated by ID3/TCF3 mutations. TCF3-
upregulated genes were more highly expressed in germinal center B cells than in resting 
or activated blood B cells and the reverse was true for TCF3-downregulated genes (Fig. 
2i; Supplementary Fig. 6a), suggesting that BL “inherits” the TCF3 gene expression 
program from its normal cellular counterpart. 
Biological insights from this analysis include the fact that the negative regulators 
of TCF3 – ID1, ID2, and ID3 – were direct targets of TCF3 transactivation, thereby 
creating a negative feedback loop (Fig. 2i; Supplementary Fig. 5a). By RNA-seq, ID3 
was 38-fold and 12-fold more highly expressed in BL than ID1 and ID2, respectively, 
accounting for the preferential mutation of ID3 in BL. TCF3 also positively regulated 
genes that play crucial roles in germinal center B cell biology (POU2AF1, CXCR4, LTB, 
CCND3). TCF3 upregulated CCND3 and E2F2 while downregulating RB1, thereby 
promoting cell cycle progression. 
Two components of the B cell receptor, the immunoglobulin heavy and light 
chains, were both upregulated by TCF3 in BL, as in normal B cells8,12 (Fig. 2i; 
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Supplementary Figs. 2i, j, 5a). In this regard, it was notable that knockdown of the BCR 
subunit CD79A was toxic for several BL lines in our RNA interference screen 
(Supplementary Fig. 7a). Two-thirds of BL lines were clearly BCR-dependent, based on 
a time-dependent decrease in their viability following knockdown of either CD79A or the 
BCR-associated kinase SYK (Fig. 3a). Unlike ABC DLBCL lines, which have a “chronic 
active” form of BCR signaling4, BL lines do not require the NF-κB pathway for survival 
since they were not killed by an IκB kinase β inhibitor and had little or no dependence on 
CARD1113, an adapter that engages NF-κB (Supplementary Fig. 7a, b, c). Rather, 
CD79A or SYK depletion in BL lines decreased AKT phosphorylation, a marker of PI(3) 
kinase signaling (Fig. 3b; Supplementary Fig. 7d), suggesting that the BCR-dependency 
in BL is akin to “tonic” BCR signaling14, a phenomenon that engages pro-survival PI(3) 
kinase signaling more than NF-κB15. 
TCF3 knockdown decreased phospho-AKT levels in all BCR-dependent lines 
tested, as did ID3 overexpression (Fig. 3b, Supplementary Figs. 7d, e), perhaps due to 
decreased cell surface BCR expression following TCF3 depletion (Fig. 3c). In addition, a 
direct TCF3 target, PTPN6, encodes the phosphatase SHP-1, an inhibitor of BCR 
signaling (Supplementary Figs. 2j, 5a). TCF3 depletion increased SHP-1 mRNA and 
protein levels, indicating TCF3 repression (Fig. 3d; Supplementary Figs. 2i, 6a). Ectopic 
provision of SHP-1 decreased phospho-AKT in BCR-dependent BL lines, suggesting that 
TCF3 repression of SHP-1 may contribute to tonic BCR signaling and PI(3) kinase 
activation in BL (Fig. 3e). 
A screen of a larger number of BL lines revealed that all had PI(3) kinase-
dependent AKT phosphorylation and engagement of the mTOR pathway, as judged by 
phosphorylation of p70 S6 kinase (Fig. 3f). Treatment of BL lines with BKM120, a PI(3) 
kinase inhibitor in clinical trials, or rapamycin, an inhibitor of the mTORC1 complex, 
was toxic to most BL lines (Fig. 3g; Supplementary Fig. 7f). Of note, both BCR-
dependent and –independent lines had constitutive PI(3) kinase signaling. Other 
mechanisms to activate PI(3) kinase in BL include PTEN mutations, which were 
infrequent (7%), and 10-fold overexpression (compared to DLBCL) of the MYC-
dependent gene MIR17HG, which encodes a microRNA that inhibits PTEN expression16 
(Supplementary Fig. 7g). To judge whether the PI(3) kinase pathway may be active in 
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primary BL tumors, we identified genes that were significantly up- or down-regulated 
following rapamycin treatment of BL lines (FDR=0.0022; Supplementary Table 7). 
Among BL and GCB DLBCL biopsies, rapamycin down-regulated genes were generally 
more highly expressed in BL (p=0.026), whereas rapamycin up-regulated genes had the 
opposite enrichment pattern (p=0.007) (Fig. 3i), suggesting that PI(3) kinase-dependent 
mTORC1 activity is a consistent feature of BL tumors. 
Another aspect of BL pathogenesis was revealed by recurrent mutations in the 
TCF3 direct target CCND3, encoding cyclin D3, a required regulator of the G1-S cell 
cycle transition in germinal center B cells17,18. CCND3 mutations were frequent in sBL 
(38%) and hivBL (67%) but not eBL (1.8%), indicating a distinct genetic pathogenesis 
for this BL subtype (Figs. 4b). At a lower frequency, CCND3 mutations were also present 
in ABC and GCB DLBCL3,6,7. Multiple nonsense and frame shift mutations removed up 
to 41 amino acids from the cyclin D3 C-terminus (Fig. 4a; Supplementary Table 8). 
Recurrent missense mutations affected threonine 283 (T283), known to be involved in D-
type cyclin phosphorylation and stability19, as well as nearby proline (P284) and 
isoleucine (I290) residues. These cyclin D3 residues were conserved in evolution, and 
similar residues are present in cyclin D1 and D2 (Fig. 4a). Most mutations were 
heterozygous and their somatic origin was confirmed in 5 cases (Supplementary Table 8). 
To explore the function of the cyclin D3 mutants, we constructed fusion proteins 
linking green fluorescent protein (GFP) to either wild-type or mutant cyclin D3. All 
mutant isoforms accumulated to more than 10-fold higher levels than the wild-type 
isoform (Fig. 4c), and pulse-chase analysis showed that the mutant cyclin D3 isoforms 
have longer half lives (Supplementary Fig. 8a). To test the oncogenic potential of the 
cyclin D3 mutants, we transduced GFP-tagged wild-type or T283A cyclin D3 into 
lymphoma lines in which endogenous cyclin D3 was knocked down. Cells transduced 
with T283A cyclin D3 had a marked proliferative advantage over untransduced cells, but 
wild-type cyclin D3 had little effect (Fig. 4d). Separately, our RNA interference screen 
revealed that BL and GCB DLBCL lines depend on cyclin D3 and CDK6, a kinase that 
partners with D-type cyclins, irrespective of CCND3 mutational status (Fig. 4e; 
Supplementary Figs. 8b, c, d, Supplementary Table 4). Hence, BL lines rely on cyclin 
D3/CDK6 for cell cycle progression, an effect augmented by oncogenic cyclin D3 
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mutations. The BL cell cycle is also deregulated by nonsense and frame shift mutations 
or homozygous deletions in CDKN2A, encoding the CDK6 inhibitor p16 (Supplementary 
Fig. 8e and Supplementary Table 8). 
To explore this pathway as a therapeutic target, we treated BL, GCB DLBCL and 
mantle cell lymphoma (MCL) lines with a CDK4/6 inhibitor (PD 0332991) daily for 2 
weeks. After an arrest in G1 phase, the BL and GCB DLBCL lines began to die by day 2, 
with a steady accumulation of apoptotic cells over time whereas the MCL line arrested in 
G1 phase but did not die (Fig. 4f). Treatment of a BL xenograft model after the 
establishment of tumors with PD 0332991 profoundly reduced tumor volume after 6 
days, resulting in the virtual disappearance of tumor cells by day 10 (Fig. 4g, 
Supplementary Fig. 8f). 
By merging functional and structural genomic data we have uncovered previously 
unappreciated pathways in BL pathogenesis, several of which are amenable to therapeutic 
attack (Fig. 4h). The majority of BL tumors acquire mutations that free TCF3 from ID3 
inhibition. These mutations “hard-wire” a TCF3 transcriptional program that is 
characteristic of germinal center B cells and distinguishes BL from other aggressive 
lymphomas. BL lines require TCF3 for survival, in part because it augments pro-survival 
PI(3) kinase signaling by intensifying a tonic form of BCR signaling. The oncogenic 
synergy between the MYC and PI(3) kinase pathways that is suggested by our study is 
supported by the generation of BL-like tumors in mice in which these two pathways are 
deregulated20. Additionally, the key role of cyclin D3/CDK6 in BL pathogenesis is 
reinforced by the identification of cyclin D3 mutants in this mouse model. 
While high-dose chemotherapy can often cure BL in younger patients from 
developed countries1, these regimens are unsafe in older patients and cannot be deployed 
in less developed regions due to immune suppression and to logistical difficulties that 
preclude effective delivery21. Hopefully, the new insights into BL pathogenesis described 
herein will prompt clinical evaluation of drugs targeting the PI(3) kinase pathway, tonic 
BCR signaling, and cyclin D3/CDK6 in BL. Eventually, the rational combination of such 
targeted agents could provide more effective and less toxic treatment of BL worldwide. 
 
Methods Summary 
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RNA-Seq was performed using established Illumina protocols on a HiSeq 2000 
sequencer. RNA interference screening and cellular toxicity assays were conducted as 
described5,13. Gene expression profiling was performed using Agilent 4x44K 
microarrays. Detailed experimental and analytic procedures are presented in 
Supplementary Methods. 
 
Supplementary Information is linked to the online version of the paper at 
www.nature.com/nature 
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Fig. 1: Recurrently mutated genes in aggressive lymphomas determined by RNA-
seq. Shown are genes that were recurrently mutated in BL based on RNA-seq analysis 
(≥4/41 samples), as well as representative genes known to be recurrently mutated in 
DLBCL. Asterisks indicate differentially mutated genes (p<0.05; Supplementary Table 
9). 
 
Figure 2: TCF3 is essential for Burkitt lymphoma viability. a, TCF3 and ID3 
mutation frequencies in lymphoid cancers. MCL: mantle cell lymphoma; MM: multiple 
myeloma. b, Location of BL mutants in the crystal structure of the dimeric TCF3 E47 B-
HLH domain10. c, Location of BL mutants in the crystal structure the ID3 HLH domain 
(pdb accession 2LFH). d, Selective toxicity of a TCF3 shRNA for BL lines. Shown is the 
fraction of GFP+, shRNA-expressing cells relative to the GFP–, shRNA-negative fraction 
at the indicated times, normalized to the day 0 values. Data are representative of 4 
experiments. e, Toxicity of wild-type (WT) but not mutant ID3 isoforms for the ID3-
mutant Namalwa BL line. Shown is the fraction of GFP+, ID3-expressing cells relative to 
the GFP–, ID3-negative cells, normalized to the day 0 values. Data are representative of 4 
experiments. f, TCF3 mutants with reduced ability to bind ID3. WT or mutant TCF3 
isoforms were coexpressed with WT ID3 in 293T cells. The indicated proteins were 
detected in total cellular extracts (input) or after anti-TCF3 immunoprecipitation (IP) 
(left). ID3 levels were quantified by densitometry and normalized to TCF3 E47 levels 
(right). g, BL-derived mutant ID3 proteins are less stable than WT ID3 and bind TCF3 
less well. Mutant or WT ID3 isoforms were expressed in the ID3-deficient Namalwa BL 
line. The indicated proteins were detected in total cellular extracts (input) or after anti-
TCF3 IP. h, N551K TCF3 is an altered specificity mutant. Shown at top are DNA base 
frequencies of the most enriched motifs in peaks bound > 4-fold more or less by N551K 
TCF3 compared to WT TCF3. The mean number (+/-s.e.m.) of the indicated motifs per 
differentially bound peak is plotted below. i, A TCF3 gene expression signature 
expressed in BL and normal germinal center B cells. Gene expression changes were 
profiled in ID3-mutant BL lines following TCF3 knockdown or WT ID3 overexpression. 
Shown are genes that were downregulated by at least 0.33 log2 in >70% of samples. 
Average expression of these genes in the indicated lymphoma subtypes based on 
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published data2 and in B cell subpopulations based on RNA-seq is shown. FS: frameshift, 
Δ: Deletion, *: nonsense. 
 
Fig. 3: Tonic BCR signaling and PI(3) kinase activity in BL. a, CD79A and SYK 
shRNAs are toxic for a subset of BL lines. Shown is the fraction of GFP+, shRNA-
expressing cells relative to the GFP–, shRNA-negative fraction at the indicated times, 
normalized to the day 0 values. BCR-dependent BL lines are depicted using red colors. 
The BCR-dependent ABC DLBCL line TMD84 is also shown. Data are representative of 
3 experiments. b, Knockdown of CD79A, SYK or TCF3 reduces PI(3) kinase activity. 
Following induction of the indicated shRNAs for 2 days, shRNA-expressing (GFP+) cells 
were analyzed by FACS for phospho-S473-AKT as a measure of PI(3) kinase activity. c, 
TCF3 regulates surface BCR expression in BL. Following induction of the indicated 
shRNAs for 1 day, surface BCR expression (CD79B) was quantified by FACS in 
shRNA-expressing (GFP+) cells. d, TCF3 suppresses PTPN6 (SHP-1) expression. A 
TCF3 shRNA was induced in BL lines for 2 days, followed by immunoblotting for the 
indicated proteins. e, SHP-1 suppresses phospho-S473-AKT in BL lines. BL lines were 
transduced with a SHP-1 expression vector (+) or empty vector (–), whereupon the 
indicated proteins were analyzed by immunoblotting. f, BL lines have constitutively PI(3) 
kinase activity. The indicated proteins were analyzed by immunoblotting, before and 
after treatment with the PI(3) kinase inhibitor LY294002. g, PI(3) kinase inhibition is 
toxic to BL lines. Viable BL cells were quantified by MTS assay following treatment for 
4 days with the indicated concentrations of the pan-class I PI(3) kinase inhibitor 
BKM120. h, A signature of rapamycin responsive genes is highly expressed in BL. 
Changes of gene expression were profiled over time in 2 BL lines following rapamycin 
(100 pM) treatment. Genes consistently downregulated in both lines were chosen (see 
Methods), and their expression in lymphoma biopsies2 is shown based on the color scale. 
PMBL: primary mediastinal B-cell lymphoma. i, The rapamycin-upregulated and –
downregulated signatures distinguish BL and GCB DLBCL. Genes are ranked according 
to their expression in BL vs. GCB DLBCL (T-statistic) and rapamycin signature genes 
are indicated with a green hash mark.  Kolmogorov-Smirnov p-values are shown.  
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Fig. 4: Oncogenic CCND3 mutations in Burkitt lymphoma a, Cyclin D3 residues 
affected by the indicated mutations in each lymphoma subtype. Amino acids 250-292 of 
NP_001751 are shown. FL: follicular lymphoma; FS: frameshift . b, Frequencies of 
CCND3 mutations in different lymphoma subtypes. c, CCND3 mutations increase protein 
stability. FACS analysis of the Gumbus BL line transduced with WT or mutant GFP-
CCND3 fusion proteins. d, The T283A cyclin D3 mutant confers a proliferation 
advantage. Expression of endogenous CCND3 was knocked down in Gumbus (BL) and 
BJAB (GCB DLBCL) cells and different GFP-CCND3 isoforms were ectopically 
expressed. The relative number of GFP-CCND3-expressing cells is plotted over time of 
shRNA and GFP-CCND3 induction, normalized to day 0. Data are representative of 3 
experiments. e, CCND3 shRNAs are selectively toxic for BL and GCB DLBCL lines. 
Shown is the fraction of GFP+, shRNA-expressing cells relative to the GFP−, shRNA-
negative fraction at the indicated times, normalized to the day 0 values. Data are 
representative of 4 experiments. f, Cell cycle block in G1 phase is lethal to cyclin D3-
mutant lymphoma lines. Lines were treated with the CDK4/6 inhibitor PD 0332991 (1 
μM) over the indicated time course and analyzed for: viable cells in G1 phase, total 
viable cells and apoptotic cells. Data were normalized as indicated and are representative 
of 3 experiments. g, Therapeutic potential of PD 0332991 revealed using a BL xenograft 
model. Immunodeficient mice bearing established subcutaneous xenografts of the 
Gumbus BL line (engineered to express luciferase) were treated with PD 0332991 (150 
mg/kg/day p.o.) for the indicated times. Tumor volumes were estimated by luciferase 
luminescence. Error bars are s.e.m. (n=3). h, Schematic of recurrent oncogenic pathways 
in Burkitt lymphoma. Gain-of-function and loss-of-function aberrations are indicated by 
plus signs and by X signs, respectively. Grey boxes indicate drugs that block these 
deregulated pathways. 
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